1. Intraperitoneal versus oral calcitriol in children on peritoneal dialysis.
| Outcome | Jones 1994a | Salusky 1998 | Summary estimateb |
| Abnormal bone biopsy | Not reported | 12/16c versus 12/17d | RR 1.06 (0.70 to 1.61) |
| Adynamic bone disease | Not reported | 7/16 versus 5/17 | RR 1.49 (0.59 to 3.74) |
| Osteitis fibrosa | Not reported | 2/16 versus 6/17 | RR 0.35 (0.08 to 1.51) |
| Mixed/mild disease | Not reported | 3/16 versus 7/17 | RR 0.46 (0.14 to 1.46) |
| Normal/reduced bone formation rate | Not reported | 11/16 versus 11/17 | RR 1.06 (0.66 to 1.72) |
| Bone formation rate (µm2/mm2/d) | Not reported | 297 ± 472 versus 586 ± 973 | MD ‐289.00 (‐806.13 to 228.13) |
| PTH (pg/mL) | No significant difference | 169 ± 228 versus 670 ± 400 | MD ‐501.00 (‐721.54 to ‐280.46) |
| Maximum serum calcium (mg/dL) | Not reported | 10.4 ± 2 versus 9.7 ± 1.64 | MD 0.70 (‐0.55 to 1.95) |
| Hypercalcaemic patients | 0/7 versus 0/7 | 8/16 versus 5/17 | RD 0.21 (‐0.12 to 0.53) |
| Hypophosphataemic patients | Not reported | 2/16 versus 3/17 | RD ‐0.05 (‐0.29 to 0.19) |
| Peritonitis episodes/patient‐month | 1/ 11 versus 1/11 | 1/12 versus 1/10 | RD 0.01 (‐0.24 to 0.26) |
| Height SDS | ‐2.26 (‐4.5 to ‐1.61) versus ‐2.33 (‐4.27 to ‐1.43) (end) | Not reported | Not calculated |
a Cross‐over study
b Summary estimate (RR, RD, MD) and 95% CI; cross‐over studies excluded
c Experimental intervention
d Comparative intervention
PTH ‐ parathyroid hormone; SDS ‐ standard deviation score